Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lupus nephritis: induction therapy.

T M Chan1

  • 1Department of Medicine, University of Hong Kong, Queen Many Hospital, Hong Kong. dtmchan@hku.hk

Lupus
|April 5, 2005
PubMed
Summary
This summary is machine-generated.

Effective induction therapy for lupus nephritis is crucial for kidney survival. Mycophenolate mofetil with corticosteroids offers a safer, effective alternative to cyclophosphamide, reducing adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incorporating the cardiovascular-kidney-metabolic health framework into the local healthcare system: a position statement from the Hong Kong College of Physicians.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

Hong Kong Academy of Medicine position paper on postgraduate medical education 2023.

Hong Kong medical journal = Xianggang yi xue za zhi·2023
Same author

B-cell signatures for disease flare and response to pre-emptive immunosuppressive therapy in patients with lupus nephritis: abridged secondary publication.

Hong Kong medical journal = Xianggang yi xue za zhi·2023
Same author

Application of virtual reality for peritoneal dialysis exchange learning in patients with end-stage renal disease and cognitive impairment.

Virtual reality·2022
Same author

Lymphocyte subset profile and clinical phenotype in lupus nephritis: abridged secondary publication.

Hong Kong medical journal = Xianggang yi xue za zhi·2022
Same author

A study on clinical outcomes of Rathke's cleft cyst in patients managed conservatively.

Pituitary·2021
Same journal

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
See all related articles

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Severe proliferative lupus nephritis requires effective induction therapy to prevent renal damage and preserve nephron mass for long-term kidney survival.
  • Corticosteroid and cyclophosphamide regimens show efficacy but carry significant, potentially fatal adverse effects.
  • Alternative treatments are needed to balance efficacy with improved safety profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of mycophenolate mofetil combined with corticosteroids as induction and maintenance therapy for severe proliferative lupus nephritis.
  • To compare the outcomes of mycophenolate mofetil-based regimens with traditional cyclophosphamide-based treatments.
  • To assess the long-term renal survival rates associated with continuous mycophenolate mofetil therapy.

Main Methods:

Related Experiment Videos

  • Review of existing data comparing corticosteroid and cyclophosphamide induction therapy.
  • Analysis of studies utilizing modified, reduced-dose cyclophosphamide regimens.
  • Evaluation of evidence supporting mycophenolate mofetil and corticosteroid combination therapy.
  • Assessment of recent data on continuous mycophenolate mofetil use for induction and maintenance.

Main Results:

  • US and European studies indicate corticosteroid and cyclophosphamide improve efficacy over corticosteroids alone, with modified regimens showing reduced adverse effects.
  • Mycophenolate mofetil, by inhibiting lymphocyte proliferation, targets a key pathogenic pathway in lupus nephritis.
  • Combined mycophenolate mofetil and corticosteroid therapy demonstrates effectiveness across diverse ethnic groups with significantly fewer adverse events than cyclophosphamide.
  • Continuous mycophenolate mofetil therapy has shown long-term efficacy in preserving renal survival.

Conclusions:

  • Mycophenolate mofetil in combination with corticosteroids is an effective and safer induction and maintenance therapy for severe proliferative lupus nephritis compared to cyclophosphamide-based regimens.
  • This approach offers a favorable long-term renal outcome with a reduced incidence of serious adverse effects.
  • Continuous mycophenolate mofetil therapy represents a promising strategy for preserving kidney function in lupus nephritis patients.